logo
Plus   Neg
Share
Email

Life Tech To Collaborate With Merck Serono For Diagnostics Development

Life Technologies Corp. (LIFE) announced that it has signed an agreement to collaborate with Merck Serono, a division of German drugmaker Merck KGaA (MKGAY.PK), for current and future companion diagnostics projects. The current agreement constitutes the first collaboration between the two companies and represents another step in Life Technologies' strategy to develop its diagnostic business through internal development, collaborations and select acquisitions.

The non-exclusive agreement covers an initial project for oncology and provides for a long-term collaboration across a potentially broad range of Life instrument platforms and a wide range of therapeutic areas. Financial terms of the agreement were not disclosed.

According to the Life Technologies, the collaboration will seek to combine the biomarkers identified by Merck's translational research with Life Technologies' proprietary platform technologies and to develop companion diagnostics concurrently with Merck's drug development programs. The collaboration will also work to simultaneously seek regulatory approval of Merck's drug and Life Technologies' companion diagnostic.

Life Technologies said it offers a variety of platform technologies that support the development of new diagnostics. These technologies span both genetic and proteomic analysis, including next-generation sequencing, Sanger sequencing, qPCR and flow cytometry, some of which have already received clearance by the Food and Drug Administration (FDA). If successful, the agreement will be followed by a commercialization agreement under which Life Technologies will commercialize the companion diagnostic in agreed upon territories.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Each year, more than eight million children die from preventable diseases in countries with the worst health care systems . Kofi Annan, former head of the UN, said that, "Almost all these deaths will happen in developing countries. A large number of them could be prevented." You do not want to find... As Canada prepares to legalize marijuana nationwide later this year, a national survey by Statistics Canada has thrown up some interesting facts - including that legal marijuana is not a temptation for most Canadians. Regardless of cannabis use, 79 percent of Canadians surveyed said they would not be more likely to try or increase their cannabis consumption just because it is legalized. The Procter & Gamble Company (PG) reported third-quarter net earnings per share of $0.95, an increase of two percent versus the prior year. Net earnings from continuing operations declined 1% year-over-year to $2.54 billion. Core earnings per share increased four percent to $1.00. On average, 20 analysts...
Follow RTT